261 related articles for article (PubMed ID: 20686035)
21. Evaluation of the immune response elicited by vaccination with viral vectors encoding FMDV capsid proteins and boosted with inactivated virus.
Romanutti C; D'Antuono A; Palacios C; Quattrocchi V; Zamorano P; La Torre J; Mattion N
Vet Microbiol; 2013 Aug; 165(3-4):333-40. PubMed ID: 23683999
[TBL] [Abstract][Full Text] [Related]
22. Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses.
Chmielewska AM; Naddeo M; Capone S; Ammendola V; Hu K; Meredith L; Verhoye L; Rychlowska M; Rappuoli R; Ulmer JB; Colloca S; Nicosia A; Cortese R; Leroux-Roels G; Balfe P; Bienkowska-Szewczyk K; Meuleman P; McKeating JA; Folgori A
J Virol; 2014 May; 88(10):5502-10. PubMed ID: 24599994
[TBL] [Abstract][Full Text] [Related]
23. Recombinant Chimpanzee Adenovirus Vaccine AdC7-M/E Protects against Zika Virus Infection and Testis Damage.
Xu K; Song Y; Dai L; Zhang Y; Lu X; Xie Y; Zhang H; Cheng T; Wang Q; Huang Q; Bi Y; Liu WJ; Liu W; Li X; Qin C; Shi Y; Yan J; Zhou D; Gao GF
J Virol; 2018 Mar; 92(6):. PubMed ID: 29298885
[TBL] [Abstract][Full Text] [Related]
24. Adenovirus-based vaccines generate cytotoxic T lymphocytes to epitopes of NS1 from dengue virus that are present in all major serotypes.
Gao G; Wang Q; Dai Z; Calcedo R; Sun X; Li G; Wilson JM
Hum Gene Ther; 2008 Sep; 19(9):927-36. PubMed ID: 18788905
[TBL] [Abstract][Full Text] [Related]
25. Chimpanzee-origin adenovirus vectors as vaccine carriers.
Tatsis N; Tesema L; Robinson ER; Giles-Davis W; McCoy K; Gao GP; Wilson JM; Ertl HC
Gene Ther; 2006 Mar; 13(5):421-9. PubMed ID: 16319951
[TBL] [Abstract][Full Text] [Related]
26. Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron A.
Sridhar S; Reyes-Sandoval A; Draper SJ; Moore AC; Gilbert SC; Gao GP; Wilson JM; Hill AV
J Virol; 2008 Apr; 82(8):3822-33. PubMed ID: 18256155
[TBL] [Abstract][Full Text] [Related]
27. Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors.
Sumida SM; Truitt DM; Kishko MG; Arthur JC; Jackson SS; Gorgone DA; Lifton MA; Koudstaal W; Pau MG; Kostense S; Havenga MJ; Goudsmit J; Letvin NL; Barouch DH
J Virol; 2004 Mar; 78(6):2666-73. PubMed ID: 14990686
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice.
Warimwe GM; Lorenzo G; Lopez-Gil E; Reyes-Sandoval A; Cottingham MG; Spencer AJ; Collins KA; Dicks MD; Milicic A; Lall A; Furze J; Turner AV; Hill AV; Brun A; Gilbert SC
Virol J; 2013 Dec; 10():349. PubMed ID: 24304565
[TBL] [Abstract][Full Text] [Related]
29. A rapid strategy for constructing novel simian adenovirus vectors with high viral titer and expressing highly antigenic proteins applicable for vaccine development.
Luo S; Zhang P; Ma X; Wang Q; Lu J; Liu B; Zhao W; Allain JP; Li C; Li T
Virus Res; 2019 Jul; 268():1-10. PubMed ID: 31108113
[TBL] [Abstract][Full Text] [Related]
30. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein.
Sumida SM; Truitt DM; Lemckert AA; Vogels R; Custers JH; Addo MM; Lockman S; Peter T; Peyerl FW; Kishko MG; Jackson SS; Gorgone DA; Lifton MA; Essex M; Walker BD; Goudsmit J; Havenga MJ; Barouch DH
J Immunol; 2005 Jun; 174(11):7179-85. PubMed ID: 15905562
[TBL] [Abstract][Full Text] [Related]
31. Construction and evaluation of novel rhesus monkey adenovirus vaccine vectors.
Abbink P; Maxfield LF; Ng'ang'a D; Borducchi EN; Iampietro MJ; Bricault CA; Teigler JE; Blackmore S; Parenteau L; Wagh K; Handley SA; Zhao G; Virgin HW; Korber B; Barouch DH
J Virol; 2015 Feb; 89(3):1512-22. PubMed ID: 25410856
[TBL] [Abstract][Full Text] [Related]
32. Effect of preexisting immunity on an adenovirus vaccine vector: in vitro neutralization assays fail to predict inhibition by antiviral antibody in vivo.
Pichla-Gollon SL; Lin SW; Hensley SE; Lasaro MO; Herkenhoff-Haut L; Drinker M; Tatsis N; Gao GP; Wilson JM; Ertl HC; Bergelson JM
J Virol; 2009 Jun; 83(11):5567-73. PubMed ID: 19279092
[TBL] [Abstract][Full Text] [Related]
33. Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.
Lorin C; Vanloubbeeck Y; Baudart S; Ska M; Bayat B; Brauers G; Clarinval G; Donner MN; Marchand M; Koutsoukos M; Mettens P; Cohen J; Voss G
PLoS One; 2015; 10(4):e0122835. PubMed ID: 25856308
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy.
Dudareva M; Andrews L; Gilbert SC; Bejon P; Marsh K; Mwacharo J; Kai O; Nicosia A; Hill AV
Vaccine; 2009 Jun; 27(27):3501-4. PubMed ID: 19464527
[TBL] [Abstract][Full Text] [Related]
35. Adenovirus vector-induced immune responses in nonhuman primates: responses to prime boost regimens.
Tatsis N; Lasaro MO; Lin SW; Haut LH; Xiang ZQ; Zhou D; Dimenna L; Li H; Bian A; Abdulla S; Li Y; Giles-Davis W; Engram J; Ratcliffe SJ; Silvestri G; Ertl HC; Betts MR
J Immunol; 2009 May; 182(10):6587-99. PubMed ID: 19414814
[TBL] [Abstract][Full Text] [Related]
36. Chimpanzee adenovirus vector-based avian influenza vaccine completely protects mice against lethal challenge of H5N1.
Cheng T; Wang X; Song Y; Tang X; Zhang C; Zhang H; Jin X; Zhou D
Vaccine; 2016 Sep; 34(41):4875-4883. PubMed ID: 27576071
[TBL] [Abstract][Full Text] [Related]
37. Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.
Andersson AC; Ragonnaud E; Seaton KE; Sawant S; Folgori A; Colloca S; Labranche C; Montefiori DC; Tomaras GD; Holst PJ
Vaccine; 2016 Oct; 34(44):5344-5351. PubMed ID: 27633665
[TBL] [Abstract][Full Text] [Related]
38. The prevalence of neutralising antibodies to chimpanzee adenovirus type 6 and type 7 in healthy adult volunteers, patients with chronic hepatitis B and patients with primary hepatocellular carcinoma in China.
Jian L; Zhao Q; Zhang S; Huang W; Xiong Y; Zhou X; Jia B
Arch Virol; 2014 Mar; 159(3):465-70. PubMed ID: 24057756
[TBL] [Abstract][Full Text] [Related]
39. Immunodominance of Adenovirus-Derived CD8
Schöne D; Hrycak CP; Windmann S; Lapuente D; Dittmer U; Tenbusch M; Bayer W
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768877
[TBL] [Abstract][Full Text] [Related]
40. Development of a targeted gene vector platform based on simian adenovirus serotype 24.
Belousova N; Mikheeva G; Xiong C; Soghomonian S; Young D; Le Roux L; Naff K; Bidaut L; Wei W; Li C; Gelovani J; Krasnykh V
J Virol; 2010 Oct; 84(19):10087-101. PubMed ID: 20631120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
